Howard Ozer, MD, PhD, known for his research on leukemias and lymphomas, was appointed director of the University of Illinois Cancer Center (UICC) in Chicago in June. He had been serving as interim director since the January 2011 death of the institution's previous leader, Gary Kruh, MD, PhD.
Among other responsibilities, Ozer will oversee the UICC application to become a National Cancer Institute–designated cancer center.
Sir Mark Walport, PhD, MB BChir, director of the Wellcome Trust in the United Kingdom (UK), has been appointed as the UK Government Chief Scientific Adviser, beginning in April 2013. Succeeding Sir John Beddington, he will help ensure that scientific knowledge informs policy decisions. Walport has led the Wellcome Trust, a global charity dedicated to funding biomedical research, since 2003.
John C. Reed, MD, PhD, chief executive officer of Sanford-Burnham Medical Research Institute in La Jolla, CA, was named editor-in-chief of Molecular Cancer Therapeutics, effective August 1. He replaces Daniel Von Hoff, MD, the journal's founding editor.
Reed earned his medical and doctoral degrees from the University of Pennsylvania School of Medicine in Philadelphia, where he also completed his clinical postdoctoral training. His research focuses on mechanisms that regulate apoptosis and how defects in apoptosis contribute to disease.
The recipient of numerous awards and honors, Reed has served on the editorial boards of several journals, including Cancer Research and Clinical Cancer Research.
For more news on cancer research, visit Cancer Discovery online at http://CDnews.aacrjournals.org.